Literature DB >> 9775343

Stability of bethanechol chloride, pyrazinamide, quinidine sulfate, rifampin, and tetracycline hydrochloride in extemporaneously compounded oral liquids.

L V Allen1, M A Erickson.   

Abstract

The stability of five drugs commonly prescribed for use in oral liquids but not commercially available as such was studied. Bethanechol chloride 5 mg/mL, pyrazinamide 10 mg/mL, quinidine sulfate 10 mg/mL, rifampin 25 mg/mL, and tetracycline hydrochloride 25 mg/mL were each prepared in a 1:1 mixture of Ora-Sweet and Ora-Plus (Paddock Laboratories), a 1:1 mixture of Ora-Sweet SF and Ora-Plus, and cherry syrup and placed in 120-mL amber clear polyethylene terephthalate bottles. Three bottles of each liquid were stored at 5 degrees C and three at 25 degrees C, all in the dark. Samples were taken initially and at various times up to 60 days for analysis by high-performance liquid chromatography and assessment of appearance and odor; pH was measured. A mean of at least 90% of the initial drug concentration was retained for 60 days in the liquids containing bethanechol chloride, pyrazinamide, or quinidine sulfate and for 28 days in the rifampin-containing liquids and the mixture of tetracycline hydrochloride and Ora-Sweet-Ora-Plus at both 5 and 25 degrees C. Tetracycline hydrochloride concentrations of 90% or more of the initial concentration were retained in the liquids prepared with Ora-Sweet SF-Ora-Plus for 10 days at 5 degrees C and 7 days at 25 degrees C and in those prepared with cherry syrup for 7 days at 5 degrees C and 2 days at 25 degrees C. No substantial changes in the appearance, odor, or pH of any liquid were observed. At 5 and 25 degrees C, bethanechol chloride 5 mg/mL, pyrazinamide 10 mg/mL, and quinidine sulfate 10 mg/mL were stable in three extemporaneously compounded oral liquids for 60 days and rifampin 25 mg/mL was stable for 28 days. The stability of tetracycline hydrochloride 25 mg/mL varied with the vehicle.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9775343     DOI: 10.1093/ajhp/55.17.1804

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  4 in total

1.  Development and chemical stability studies of alcohol-free phenobarbital solution for use in pediatrics: a technical note.

Authors:  M Jelveghari; A Nokhodchi
Journal:  AAPS PharmSciTech       Date:  2008-08-07       Impact factor: 3.246

2.  Osmolality of Commonly Used Oral Medications in the Neonatal Intensive Care Unit.

Authors:  Dhara D Shah; Andriy Kuzmov; Dana Clausen; Anita Siu; Christine A Robinson; Katelin Kimler; Rachel Meyers; Pooja Shah
Journal:  J Pediatr Pharmacol Ther       Date:  2021-02-15

3.  Comparison Study of Airway Reactivity Outcomes due to a Pharmacologic Challenge Test: Impulse Oscillometry versus Least Mean Squared Analysis Techniques.

Authors:  Elena Rodriguez; Charrell M Bullard; Milena H Armani; Thomas L Miller; Thomas H Shaffer
Journal:  Pulm Med       Date:  2013-04-11

4.  Concurrent Quinidine and Phenobarbital in the Treatment of a Patient with 2 KCNT1 Mutations.

Authors:  Camerin C Passey; John Erramouspe; Peter Castellanos; Elizabeth C O'Donnell; David M Denton
Journal:  Curr Ther Res Clin Exp       Date:  2019-02-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.